A nephrotoxicity-free, iron-based contrast agent for magnetic resonance imaging of tumors.

摘要: Abstract Gadolinium-based contrast agents (GBCAs) are the most widely used T1 for magnetic resonance imaging (MRI) and have achieved remarkable success in clinical cancer diagnosis. However, GBCAs could cause severe nephrogenic systemic fibrosis to patients with renal insufficiency. Nevertheless, quickly excreted from kidneys, which shortens their window prevents long-term monitoring of disease per injection. Herein, a nephrotoxicity-free MRI agent is developed by coordinating ferric iron into telodendritic, micellar nanostructure. This new nano-enabled, iron-based (nIBCA) not only can reduce accumulation relieve kidney burden, but also exhibit significantly higher tumor noise ratio (TNR) In comparison Magnevist (a clinical-used GBCA), induces obvious nephrotoxicity while nIBCA does not, indicating that such novel may be applicable renally compromised requiring contrast-enhanced MRI. The precisely image subcutaneous brain tumors mouse model effective lasted at least 24 h. highlights intracranial high TNR. presents potential alternative as it has superior biocompatibility, TNR window.